Executive Director - Infectious Disease and Vaccines
Merck & Co., Inc.
Disclosure: Merck & Co., Inc. (Employee, Shareholder)
Jay Grobler is Executive Director, Infectious Disease and Vaccines at Merck. He currently leads early clinical development for infectious disease programs and oversees biology for pipeline and marketed infectious disease products including treatments for HIV-1 infection and COVID-19. Before assuming this role, Dr. Grobler had leadership roles in discovery and early clinical development focused on identifying new agents for treatment of infectious diseases.
Among his contributions, Dr. Grobler carried out seminal studies on the mechanism of action of HIV integrase inhibitors that contributed to the identification of Isentress. More recently, he led the preclinical and early clinical development of islatravir, a first-in-class nonnucleoside reverse transcriptase translocation inhibitor (NRTTI; currently in phase 3 clinical development for treatment and prophylaxis of HIV infection).
Dr. Grobler received his undergraduate and graduate degrees in Biochemistry and Molecular Biology from the University of Miami in Miami, Florida, and subsequently competed training as an IRTA Fellow at the National Institutes of Health in Bethesda, Maryland, before joining Merck in 1997.